Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease

Molecular Biology Reports

Volumn 41, Issue 3, 2014, Pages 1317-1323

  Ye, Zi ^a   Wang, Suijun ^b   Yang, Zhen ^c   He, Min ^a   Zhang, Shuo ^a   Zhang, Weiwei ^c   Wen, Jie ^a   Li, Qin ^a   Huang, Ying ^a   Wang, Xuanchun ^a   Lu, Bin ^a   Zhang, Zhaoyun ^a   Su, Qing ^c   Hu, Renming ^a  

^a FUDAN UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cathepsin S; Chemerin; Inflammation; Lipocalin 2; Nonalcoholic fatty liver disease

Indexed keywords

CATHEPSIN S; CHEMERIN; INSULIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADIPOCYTE; ADULT; ARTICLE; B SCAN; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS;

ACUTE-PHASE PROTEINS; AGED; CATHEPSINS; CHEMOKINES; FATTY LIVER; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPOCALINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS;

EID: 84896055674     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-013-2977-5     Document Type: Article

References (38)

1. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R (2006) Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 26:856-863 (Pubitemid 44165254)
2. Musso G, Gambino R, Cassader M (2010) Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 11:430-445
3. Musso G, Gambino R, Cassader M, Pagano G (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617-649
4. Feldstein AE (2010) Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30:391-401
5. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, London R, Peduto T, Chisholm DJ, George J (2008) Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 48:449-457
6. Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169-2180 (Pubitemid 46693756)
7. Jin D, Guo H, Bu SY, Zhang Y, Hannaford J, Mashek DG, Chen X (2011) Lipocalin 2 is a selective modulator of peroxisome proliferator-activated receptor-gamma activation and function in lipid homeostasis and energy expenditure. FASEB J 25:754-764
8. Guo H, Jin D, Zhang Y, Wright W, Bazuine M, Brockman DA, Bernlohr DA, Chen X (2010) Lipocalin-2 deficiency impairs thermogenesis and potentiates diet-induced insulin resistance in mice. Diabetes 59:1376-1385
9. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A (2007) Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 53:34-41 (Pubitemid 46047761)
10. Chapman HA, Riese RJ, Shi GP (1997) Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59:63-88 (Pubitemid 27142435)
11. Petanceska S, Canoll P, Devi LA (1996) Expression of rat cathepsin S in phagocytic cells. J Biol Chem 271:4403-4409 (Pubitemid 26070548)
12. Taleb S, Lacasa D, Bastard JP, Poitou C, Cancello R, Pelloux V, Viguerie N, Benis A, Zucker JD, Bouillot JL, Coussieu C, Basdevant A, Langin D, Clement K (2005) Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis. FASEB J 19:1540-1542 (Pubitemid 41279024)
13. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M, Sasaki S (2007) Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 362:1013-1018 (Pubitemid 47390675)
14. Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Ciupinska-Kajor M, Berdowska A, Wozniak-Grygiel E, Buldak R (2010) Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 45:235-242
15. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, Tordjman J, Eckel J, Clément K (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 95:2892-2896
16. Huang Y, Yang Z, Ye Z, Li Q, Wen J, Tao X, Chen L, He M, Wang X, Lu B, Zhang Z, Zhang W, Qu S, Hu R (2012) Lipocalin-2, glucose metabolism and chronic low-grade systemic inflammation in Chinese people. Cardiovasc Diabetol 11:11
17. Yang Z, Wang X, Wen J, Ye Z, Li Q, He M, Lu B, Ling C, Wu S, Hu R (2011) Prevalence of non-alcoholic fatty liver disease and its relation to hypoadiponectinaemia in the middle-aged and elderly Chinese population. Arch Med Sci 7:665-672
18. Lu B, Yang Z, Wang M, Yang Z, Gong W, Yang Y, Wen J, Zhang Z, Zhao N, Zhu X, Hu R (2007) High prevalence of albuminuria in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract 75:184-192 (Pubitemid 44894601)
19. Yang Z, Zhang Z, Wen J, Wang X, Lu B, Yang Z, Zhang W, Wang M, Feng X, Ling C, Wu S, Hu R (2010) Elevated serum chemokine CXC ligand 5 levels are associated with hypercholesterolemia but not a worsening of insulin resistance in Chinese people. J Clin Endocrinol Metab 95:3926-3932
20. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J (2009) Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 49:1926-1934
21. Law IK, Xu A, Lam KS, Berger T, Mak TW, Vanhoutte PM, Liu JT, Sweeney G, Zhou M, Yang B, Wang Y (2010) Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity. Diabetes 59:872-882
22. Esteve E, Ricart W, Fernández-Real JM (2009) Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 32(Suppl 2):362-367
23. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH (2009) Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 116:539-564
24. Playford RJ, Belo A, Poulsom R, Fitzgerald AJ, Harris K, Pawluczyk I, Ryon J, Darby T, Nilsen-Hamilton M, Ghosh S, Marchbank T (2006) Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology 131:809-817 (Pubitemid 44307059)
25. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:1877-1887
26. Magister S, Obermajer N, Mirković B, Svajger U, Renko M, Softić A, Romih R, Colbert JD, Watts C, Kos J (2012) Regulation of cathepsins S and L by cystatin F during maturation of dendritic cells. Eur J Cell Biol 91:391-401
27. Naour N, Rouault C, Fellahi S, Lavoie ME, Poitou C, Keophiphath M, Eberlé D, Shoelson S, Rizkalla S, Bastard JP, Rabasa-Lhoret R, Clément K, Guerre-Millo M (2010) Cathepsins in human obesity: changes in energy balance predominantly affect cathepsin s in adipose tissue and in circulation. J Clin Endocrinol Metab 95:1861-1868
28. Pan L, Li Y, Jia L, Qin Y, Qi G, Cheng J, Qi Y, Li H, Du J (2012) Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One 7:e35315
29. Jobs E, Risérus U, Ingelsson E, Helmersson J, Nerpin E, Jobs M, Sundström J, Lind L, Larsson A, Basu S, Arnlöv J (2010) Serum cathepsin S is associated with serum C-reactive protein and interleukin-6 independently of obesity in elderly men. J Clin Endocrinol Metab 95:4460-4464
30. Yang Z, Wen J, Li Q, Tao X, Ye Z, He M, Zhang W, Huang Y, Chen L, Ling C, Qu S, Hu R (2012) PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Mol Cell Endocrinol 348:255-259
31. Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C, Wu S, Hu R (2010) Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep 38:1145-1150
32. Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg N, John H, Richter R, Schleuder D, Meyer M, Forssmann WG (2003) Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett 555:495-499 (Pubitemid 37532599)
33. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C (2010) Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 72:342-348
34. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148:4687-4694 (Pubitemid 47481514)
35. Ernst MC, Sinal CJ (2010) Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 21:660-667
36. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB (2010) Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology 151:2590-2602
37. Stejskal D, Karpisek M, Hanulova Z, Svestak M (2008) Chemerin is an independent marker of the metabolic syndrome in a Caucasian population - a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152:217-221
38. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E (2011) Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 46:91-97